Skip to Main Content
Contribute Try STAT+ Today

The pricey Imbruvica cancer treatment that became available seven years ago could have its monopoly extended through 2036 thanks to dozens of patents and, as a result, consumers may be forced to spend an extra $41 billion for the medicine by then, according to a new analysis.

Since the first patent application was filed in 2006, the drug has been the subject of a blizzard of applications that has yielded no less than 88 patents. In fact, more than half of the 165 applications were filed after Food and Drug Administration approval in 2013, and most of those cover different indications or formulations, not the active ingredient in the drug itself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Insightful observation – “There’s probably more innovation in the legal drafting of the patents than the drug research.”

Comments are closed.